Diabetes Drug Linked to Increased Risk of Blinding Eye Disease, Study Finds
A recent retrospective matched cohort study has revealed a link between the widely-used diabetes medication semaglutide and an increased risk of nonarteritic anterior ischemic optic neuropathy (NAION), a serious eye condition that can lead to blindness.1 This discovery raises significant concerns for patients with type 2 diabetes or overweight/obesity who are prescribed semaglutide for weight loss or glycemic control. Here are the study’s findings that examine the potential implications for patients and healthcare providers alike. What is NAION? NAION is a rare but serious eye condition that can lead to irreversible blindness. It affects the optic nerve, which is responsible …










